Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

被引：0

作者：

Shimozato, Naotaka ^{[1
]}

Namisaki, Tadashi ^{[1
]}

Moriya, Kei ^{[1
]}

Kitade, Mitsuteru ^{[1
]}

Takeda, Kousuke ^{[1
]}

Kawaratani, Hideto ^{[1
]}

Kaji, Kosuke ^{[1
]}

Okura, Yasushi ^{[1
]}

Takaya, Hiroaki ^{[1
]}

Sawada, Yasuhiko ^{[1
]}

Nishimura, Norihisa ^{[1
]}

Sato, Shinya ^{[1
]}

Saikawa, Soichiro ^{[1
]}

Seki, Kenichiro ^{[1
]}

Furukawa, Masanori ^{[1
]}

Nakanishi, Keisuke ^{[1
]}

Kubo, Takuya ^{[1
]}

Yoshiji, Hitoshi ^{[1
]}

机构：

[1] Nara Med Univ, Kashihara, Nara, Japan

来源：

HEPATOLOGY | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2000

引用

页码：1059A / 1059A

页数：1

共 32 条

[21] Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function
Asuka Morita
Eri Mukai
Ayano Hiratsuka
Tomozumi Takatani
Toshihiko Iwanaga
Eun Young Lee
Takashi Miki
Endocrine, 2016, 51 : 429 - 439
[22] Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function
Morita, Asuka
Mukai, Eri
Hiratsuka, Ayano
Takatani, Tomozumi
Iwanaga, Toshihiko
Lee, Eun Young
Miki, Takashi
ENDOCRINE, 2016, 51 (03) : 429 - 439
[23] Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
Tong, Yan
Huang, Jian Qing
Chen, Yang
Tu, Mei
Wang, Wei
FRONTIERS IN PHARMACOLOGY, 2023, 14
[24] Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
Ozutsumi, Takahiro
Namisaki, Tadashi
Shimozato, Naotaka
Kaji, Kosuke
Tsuji, Yuki
Kaya, Daisuke
Fujinaga, Yukihisa
Furukawa, Masanori
Nakanishi, Keisuke
Sato, Shinya
Sawada, Yasuhiko
Saikawa, Soichiro
Kitagawa, Koh
Takaya, Hiroaki
Kawaratani, Hideto
Kitade, Mitsuteru
Moriya, Kei
Noguchi, Ryuichi
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
[25] Effects of a TGR5 Bile Acid Receptor Agonist and a Dipeptidyl Peptidase-4 Inhibitor on Dextran Sulfate Sodium-Induced Colitis in Mice
Sakanaka, Taisuke
Inoue, Takuya
Narabayashi, Ken
Fujiwara, Kaori
Okada, Toshihiko
Nouda, Sadaharu
Kuramoto, Takanori
Ishida, Kumi
Kawakami, Ken
Abe, Yosuke
Takeuchi, Toshihisa
Tokioka, Satoshi
Umegaki, Eiji
Higuchi, Kazuhide
GASTROENTEROLOGY, 2013, 144 (05) : S717 - S717
[26] Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon- like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes
Nauck, Michael A.
Kahle, Melanie
Baranov, Oleg
Deacon, Carolyn F.
Holst, Jens J.
DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 200 - 207
[27] Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis
Sawada, Yasuhiko
Kawaratani, Hideto
Kubo, Takuya
Fujinaga, Yukihisa
Furukawa, Masanori
Saikawa, Soichiro
Sato, Shinya
Seki, Kenichiro
Takaya, Hiroaki
Okura, Yasushi
Kaji, Kosuke
Shimozato, Naotaka
Mashitani, Tsuyoshi
Kitade, Mitsuteru
Moriya, Kei
Namisaki, Tadashi
Akahane, Takemi
Mitoro, Akira
Yamao, Junichi
Yoshiji, Hitoshi
HEPATOLOGY RESEARCH, 2019, 49 (03) : 284 - 295
[28] Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis
Sawada, Yasuhiko
Kawaratani, Hideto
Kubo, Takuya
Fujinaga, Yukihisa
Furukawa, Masanori
Saikawa, Soichiro
Sato, Shinya
Seki, Kenichiro
Takaya, Hiroaki
Okura, Yasushi
Kaji, Kosuke
Shimozato, Naotaka
Kitade, Mitsuteru
Moriya, Kei
Namisaki, Tadashi
Akahane, Takemi
Yoshiji, Hitoshi
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E545 - E546
[29] Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (< 50 years) obese patients with type 2 diabetes mellitus
Van Gaal, Luc
Souhami, Elisabeth
Zhou, Tianyue
Aronson, Ronnie
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2014, 1 (02): : 31 - 37
[30] Effects of Sitagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Tumor Progression and p62/SQSTM1 Subcellular Localization in a Mouse Model of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Kawaguchi, Takumi
Taniguchi, Eitaro
Itou, Minoru
Oriishi, Tetsuharu
Torimura, Takuji
GASTROENTEROLOGY, 2015, 148 (04) : S1014 - S1014

← 1 2 3 4 →